Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Broad-spectrum antibiotics prior to T-cell engagers associated w/ significantly inferior 1-year OS (60 vs 77%) and PFS (26 vs 53%) and higher relapse incidence; microbiota composition correlated w/ therapy response and toxicity.”
Title: Antibiotic-associated dysbiosis and bispecific antibody outcomes in multiple myeloma
Authors: Magdalena Corona, Roberto García-Vicente, Adolfo Saez-Marin, Raquel Ancos-Pintado, Alba Rodríguez-Garcia, Andrés Arroyo, Alberto Blanco, Ajai Chari, Thomas Martin, Jeffrey Wolf, Beatriz Rey-Bua, Maria-Victoria Mateos, Martin Kortüm, Christine Riedhammer, Luis Tamariz-Amador, Evelyn Valencia, Paula Rodríguez-Otero, Jesús San Miguel, Gladys Ibarra, Albert Oriol, Maria Teresa Cedena, Nieves López-Muñoz, Rafael Alonso, Maria Calbacho, Jose Sánchez-Pina, María Linares, Joaquín Martínez-López
You can read the Full Article in Journal for ImmunoTherapy of Cancer.
You can find other articles featuring Robert Z. Orlowski on OncoDaily.
